When AI and Genomics Collide
Today’s episode continues our coverage from a16z’s recent AI Revolution event. You’ll hear a16z Bio & Health GP Vijay Pande speak with Daphne Koller about the fascinating convergence of machine learning and genomics – two industries that have benefitted decades of investment and progress – which are now colliding head on.
Daphne is a prominent innovator at this intersection, as a long-time professor in computer science at Stanford and co-founder of Coursera, who has decided to step back into the arena with her company Insitro. In fact, Insitro is a blend of in silico and in virto!
If you’d like to access all the talks from AI Revolution in full, visit a16z.com/airevolution.
Resources:
Find Daphne on Twitter: https://twitter.com/DaphneKoller
Find Vijay on Twitter: https://twitter.com/vijaypande
Find Insitro on Twitter: https://twitter.com/insitro
Stay Updated:
Find a16z on Twitter: https://twitter.com/a16z
Find a16z on LinkedIn: https://www.linkedin.com/company/a16z
Subscribe on your favorite podcast app: https://a16z.simplecast.com/
Follow our host: https://twitter.com/stephsmithio
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Stay Updated:
Find a16z on YouTube: YouTube
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
How AI can make drug discovery fail less, with Daphne Koller from Insitro
Life-saving therapeutics continue to grow more costly to discover. At the same time, recent advances in using machine learning for the life sciences and medicine are extraordinary. Are we on the verge of a paradigm shift in biotech?
This week on the podcast, a pioneer in AI, Daphne Koller, joins Sarah Guo and Elad Gil on the podcast to help us explore that question. Daphne is the CEO and founder of Insitro — a company that applies machine learning to pharma discovery and development, specifically by leveraging “induced pluripotent stem cells.” We explain Insitro’s approach, why they’re focused on generating their own data, why you can’t cure schizophrenia in mice, and how to design a culture that supports both research and engineering. Daphne was previously a computer science professor at Stanford, and co-founder and co-CEO of edutech company Coursera.
Show Links:
Insitro - About
Video: AWS re:Invent 2019 – Daphne Koller of insitro Talks About Using AWS to Transform Drug Development
Sign up for new podcasts every week. Email feedback to show@no-priors.com
Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @DaphneKoller
Show Notes:
[1:49] - How Daphne combined her biology and tech interests and ran a bifurcated lab at Stanford
[4:34] - Why Daphne resigned an endowed chair at Stanford to build Coursera
[14:14] - How insitro approaches target identification problems and training data
[18:33] - What are pluripotent stem cells and how insitro identifies individual neurons
[24:08 ] - How insitro operates as an engine for drug discovery and partners to create the drugs themselves
[26:48] - Role of regulations, clinical trials and disease progression in drug delivery
[33:19] - Building a team and workplace culture that can bridge both bio and computer sciences
[39:50] - What Daphne is paying attention to in the so-called golden age of machine learning
[43:12] - Advice for leading a startup in edtech and healthtech
Daphne Koller — Digital Biology and the Next Epoch of Science
From teaching at Stanford to co-founding Coursera, insitro, and Engageli, Daphne Koller reflects on the importance of education, giving back, and cross-functional research.
Daphne Koller is the founder and CEO of insitro, a company using machine learning to rethink drug discovery and development. She is a MacArthur Fellowship recipient, member of the National Academy of Engineering, member of the American Academy of Arts and Science, and has been a Professor in the Department of Computer Science at Stanford University. In 2012, Daphne co-founded Coursera, one of the world's largest online education platforms. She is also a co-founder of Engageli, a digital platform designed to optimize student success.
https://www.insitro.com/
https://www.insitro.com/jobs
https://www.engageli.com/
https://www.coursera.org/
Follow Daphne on Twitter: https://twitter.com/DaphneKoller
https://www.linkedin.com/in/daphne-koller-4053a820/
Topics covered:
0:00 Giving back and intro
2:10 insitro's mission statement and Eroom's Law
3:21 The drug discovery process and how ML helps
10:05 Protein folding
15:48 From 2004 to now, what's changed?
22:09 On the availability of biology and vision datasets
26:17 Cross-functional collaboration at insitro
28:18 On teaching and founding Coursera
31:56 The origins of Engageli
36:38 Probabilistic graphic models
39:33 Most underrated topic in ML
43:43 Biggest day-to-day challenges
Get our podcast on these other platforms:
Apple Podcasts: http://wandb.me/apple-podcasts
Spotify: http://wandb.me/spotify
Google: http://wandb.me/google-podcasts
YouTube: http://wandb.me/youtube
Soundcloud: http://wandb.me/soundcloud
Tune in to our bi-weekly virtual salon and listen to industry leaders and researchers in machine learning share their research:
http://wandb.me/salon
Join our community of ML practitioners where we host AMA's, share interesting projects and meet other people working in Deep Learning:
http://wandb.me/slack
Our gallery features curated machine learning reports by researchers exploring deep learning techniques, Kagglers showcasing winning models, and industry leaders sharing best practices:
https://wandb.ai/gallery
E1089 The Next Unicorns E11: insitro CEO Daphne Koller is revolutionizing drug discovery via machine learning & data, shares insights on remote education from time at Coursera & more
Follow Daphne: https://twitter.com/DaphneKoller
Check out insitro: https://insitro.com/
Follow Jason: https://linktr.ee/calacanis
#93 – Daphne Koller: Biomedicine and Machine Learning
Daphne Koller is a professor of computer science at Stanford University, a co-founder of Coursera with Andrew Ng and Founder and CEO of insitro, a company at the intersection of machine learning and biomedicine.
Support this podcast by signing up with these sponsors:
– Cash App – use code “LexPodcast” and download:
– Cash App (App Store): https://apple.co/2sPrUHe
– Cash App (Google Play): https://bit.ly/2MlvP5w
EPISODE LINKS:
Daphne’s Twitter: https://twitter.com/daphnekoller
Daphne’s Website: https://ai.stanford.edu/users/koller/index.html
Insitro: http://insitro.com
This conversation is part of the Artificial Intelligence podcast. If you would like to get more information about this podcast go to https://lexfridman.com/ai or connect with @lexfridman on Twitter, LinkedIn, Facebook, Medium, or YouTube where you can watch the video versions of these conversations. If you enjoy the podcast, please rate it 5 stars on Apple Podcasts, follow on Spotify, or support it on Patreon.
Here’s the outline of the episode. On some podcast players you should be able to click the timestamp to jump to that time.
OUTLINE:
00:00 – Introduction
02:22 – Will we one day cure all disease?
06:31 – Longevity
10:16 – Role of machine learning in treating diseases
13:05 – A personal journey to medicine
16:25 – Insitro and disease-in-a-dish models
33:25 – What diseases can be helped with disease-in-a-dish approaches?
36:43 – Coursera and education
49:04 – Advice to people interested in AI
50:52 – Beautiful idea in deep learning
55:10 – Uncertainty in AI
58:29 – AGI and AI safety
1:06:52 – Are most people good?
1:09:04 – Meaning of life
Machine Learning: A New Approach to Drug Discovery with Daphne Koller - #332
Today we’re joined by Daphne Koller, co-Founder and former co-CEO of Coursera and Founder and CEO of Insitro. In our conversation, discuss the current landscape of pharmaceutical drugs and drug discovery, including the current pricing of drugs, and an overview of Insitro’s goal of using ML as a “compass” in drug discovery. We also explore how Insitro functions as a company, their focus on the biology of drug discovery and the landscape of ML techniques being used, Daphne’s thoughts on AutoML, and
Episode 29 - Daphne Koller
Daphne Koller, formerly at Stanford University and cofounder of the online education company, Coursera, talks this week about using machine-learning to develop new drugs. Her approach is to use machine learning to accuratley identify cellular or genetic targets for treatment. The field is just getting started but promises to speed the development of new and better therapies to treat disease.
a16z Podcast: Breaking Into Bio
with Atul Butte (@atulbutte), Daphne Koller (@daphnekoller), and Vijay Pande (@vijaypande)
Whether you’re an academic seeking to move out of research and into industry, or simply interested in working at a bio startup, this episode of the a16z Podcast is for you. It covers everything from how to build a brand in the space when you don’t have one to how the bio and how the healthcare startup ecosystem is different from traditional tech (or traditional pharma), to how to choose the right co-founder -- or even identify what problems to solve and build a company around.
The discussion (which is based on a recent event at Andreessen Horowitz) features Atul Butte, Distinguished Professor and Director of the Institute for Computational Health Sciences at UCSF; and Daphne Koller, founder and CEO of insitro (former professor at Stanford, co-founder of Coursera); in conversation with a16z bio team general partner Vijay Pande. Together, they provide practical how-to's -- for those coming from machine and deep learning backgrounds, but also for anyone, really -- for how to break into the bio space.
The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation.
This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/.
Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.
Stay Updated:
Find a16z on YouTube: YouTube
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Recode Decode: Daphne Koller, president, Coursera
Coursera president and co-founder Daphne Koller talks with Recode's Kara Swisher about how she helped build the popular online learning platform after a successful early experiment at Stanford University. Koller says the future of higher education is a mixture of online and offline learning, with people continually going back to school in some form throughout their lives, rather than stopping in their 20s. She discusses whether universities themselves are at risk of going extinct and whether technologies like artificial intelligence and virtual reality could replace a college professor.
Learn more about your ad choices. Visit podcastchoices.com/adchoices
.jpg?width=400){kind=small}